Obermatt
See Similar Stocks →

BioNTech

NSQ:BNTX · US09075V1026
BiotechnologyLarge

360

11
Profit price61
Owner Earnings Yield1
Dividend Yield1
Price/Sales34
EV / Gross Profit100
Price/Book63
Return on Capital54
Cash Return on Capital49
Return on Equity55
EBIT Margin18
Gross Profitability30
Accruals54
Owner Earnings Margin35
Sales growth18
Profit Growth1
Long-Term EPS Growth38
Reinvestment45
Price momentum27
Debt load85
Refinancing58
Debt Payback1
Liquidity18
Analyst ratings41
Opinion Changes74
Price Target Upside56
Market mood39
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

BioNTech doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryGermany
IndustryBiotechnology
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded2008
Employees4,504
Websitebiontech.com
ISINUS09075V1026
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyHealth DiagnosticsGeneticsInfectious DiseasesStem Cell TherapyOncologyVaccinesBiopharmaBiotechnologyHealth CarePharmaceutical

Description

BioNTech SE operates as a next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases and other serious diseases. The company’s fully integrated model combines decades of research in immunology with a multi-t…

Analysis

Middle-of-the-road

BioNTech SE is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
43
2026

All-time high

43

Jun 2026

All-time low

13

Mar 2026

Average rank

28

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
34
—
—
—
Price/Earnings
81
—
—
—
Price/Book
63
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
73
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare BioNTech with its peers
Immatics
NAQ:IMTX
31
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Tiziana Life Sciences
NAQ:TLSA
67
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Genmab
CPH:GMAB
40
CountryDenmark
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
OSE Immunotherapeutics
PAR:OSE
31
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Genfit
PAR:GNFT
32
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →